טוען...

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells

The role of invariant natural killer T (iNKT) cells in antitumor immunity has been studied extensively, and clinical trials in patients with advanced cancer have revealed a prolonged survival in some cases. In recent years, humanized blocking antibodies against co-stimulatory molecules such as PD-1...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Immunol Immunother
Main Authors: Kamata, Toshiko, Suzuki, Akane, Mise, Naoko, Ihara, Fumie, Takami, Mariko, Makita, Yuji, Horinaka, Atsushi, Harada, Kazuaki, Kunii, Naoki, Yoshida, Shigetoshi, Yoshino, Ichiro, Nakayama, Toshinori, Motohashi, Shinichiro
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer Berlin Heidelberg 2016
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099366/
https://ncbi.nlm.nih.gov/pubmed/27631416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1901-y
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!